Hikma signs an exclusive license and supply agreement with Octapharma for Octaplex
Deal adds the first plasma-derived treatment to Hima's product offering.
Hikma Pharmaceuticals has signed an exclusive license and supply agreement with Octapharma for Octaplex, a leading four-factor prothrombin complex concentrate (PCC). Octaplex provides a balanced content of coagulation factors II, VII, IX, X and of protein C and S. Octaplex is a recommended therapy for prophylaxis and treatment of bleeding in acquired or congenital coagulation disorders associated with deficiency of the prothrombin complex factors.
Under the terms of the agreement, Hikma will have the exclusive rights to register, distribute and market Octaplex in major countries across MENA, leveraging Hikma’s strong local presence, sales and marketing capabilities and regulatory expertise.
Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said: “We are delighted to be partnering with Octapharma, one of the largest human protein manufacturers in the world, to enhance our growing portfolio of innovative, high value products in the MENA and add the first plasma derived treatment to our product offering. Bringing this life-saving product to the region reinforces our commitment to increasing patients’ access to high-quality medicines.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.